However, when considering EGFR FISH(+) as a favorable factor, EGFR FISH(+) NSCLC patients integrated with EGFR wild/RG(+) had longer PFS than those with EGFR FISH(−) (3.3 months vs. 2.0 months, HR = 0.60, 95% CI = 0.43–0.82), and this improved trend continued to OS (16.6 months vs. 13.9 months, HR = 0.64, 95% CI = 0.43–0.95). Here, EGFR is linked to non-small cell lung carcinoma.